Expression of hypoxia-inducible factor-1α and hepatocyte growth factor in development of fibrosis in the transplanted kidney

Transplant International

Volumn 28, Issue 2, 2015, Pages 180-190

  Kellenberger, Terese ^a   Marcussen, Niels ^b   Nyengaard, Jens R ^a   Wogensen, Lise ^a   Jespersen, Bente ^c  

^a AARHUS UNIVERSITY   (Denmark)

^b ODENSE UNIVERSITY HOSPITAL   (Denmark)

^c AARHUS UNIVERSITY HOSPITAL   (Denmark)

Author keywords

fibrosis; graft survival; hepatocyte growth factor; hypoxia inducible factor 1 ; renal transplantation

Indexed keywords

AZATHIOPRINE; CYCLOSPORIN; HYPOXIA INDUCIBLE FACTOR 1ALPHA; LEUKOCYTE ANTIGEN; PREDNISOLONE; SCATTER FACTOR;

ARTICLE; BANFF SCORE; CLINICAL ARTICLE; CLINICAL PROTOCOL; CONTROLLED STUDY; DISEASE COURSE; GRAFT RECIPIENT; GRAFT SURVIVAL; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY BIOPSY; KIDNEY FIBROSIS; KIDNEY GRAFT; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; SCORING SYSTEM; ADULT; FEMALE; FIBROSIS; GLOMERULUS FILTRATION RATE; KIDNEY; MALE; MIDDLE AGED; PATHOLOGY; PHYSIOLOGY;

ADULT; FEMALE; FIBROSIS; GLOMERULAR FILTRATION RATE; GRAFT SURVIVAL; HEPATOCYTE GROWTH FACTOR; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; KIDNEY; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED;

EID: 84920920704     PISSN: 09340874     EISSN: 14322277     Source Type: Journal    
DOI: 10.1111/tri.12475     Document Type: Article

References (57)

1. Paul LC,. Chronic allograft nephropathy: an update. Kidney Int 1999; 56: 783.
2. Terasaki PI, Cecka JM, Gjertson DW, Cho Y, Takemoto S, Cohn M,. A ten-year prediction for kidney transplant survival. Clin Transpl 1992; 6: 501.
3. Li C, Yang CW,. The pathogenesis and treatment of chronic allograft nephropathy. Nat Rev Nephrol 2009; 5: 513.
4. Hocker B, Tonshoff B,. Treatment strategies to minimize or prevent chronic allograft dysfunction in pediatric renal transplant recipients: an overview. Paediatr Drugs 2009; 11: 381.
5. Gelens MA, Steegh FM, van Hooff JP, et al,. Immunosuppressive regimen and interstitial fibrosis and tubules atrophy at 12 months postrenal transplant. Clin J Am Soc Nephrol 2012; 7: 1010.
6. Del PD, Ceol M, Anglani F, et al,. Early activation of fibrogenesis in transplanted kidneys: a study on serial renal biopsies. Exp Mol Pathol 2009; 87: 141.
7. Eddy AA,. Can renal fibrosis be reversed? Pediatr Nephrol 2005; 20: 1369.
8. Heyman SN, Khamaisi M, Rosen S, Rosenberger C,. Renal parenchymal hypoxia, hypoxia response and the progression of chronic kidney disease. Am J Nephrol 2008; 28: 998.
9. Liu Y,. Cellular and molecular mechanisms of renal fibrosis. Nat Rev Nephrol 2011; 7: 684.
10. Mannon RB,. Therapeutic targets in the treatment of allograft fibrosis. Am J Transplant 2006; 6: 867.
11. Farris AB, Colvin RB,. Renal interstitial fibrosis: mechanisms and evaluation. Curr Opin Nephrol Hypertens 2012; 21: 289.
12. Boor P, Floege J,. Chronic kidney disease growth factors in renal fibrosis. Clin Exp Pharmacol Physiol 2011; 38: 441.
13. Rosenberger C, Rosen S, Heyman SN,. Current understanding of HIF in renal disease. Kidney Blood Press Res 2005; 28: 325.
14. Chen R, Xu M, Hogg RT, et al,. The acetylase/deacetylase couple CREB-binding protein/Sirtuin 1 controls hypoxia-inducible factor 2 signaling. J Biol Chem 2012; 287: 30800.
15. Rosenberger C, Mandriota S, Jurgensen JS, et al,. Expression of hypoxia-inducible factor-1alpha and -2alpha in hypoxic and ischemic rat kidneys. J Am Soc Nephrol 2002; 13: 1721.
16. Bernhardt WM, Warnecke C, Willam C, Tanaka T, Wiesener MS, Eckardt KU,. Organ protection by hypoxia and hypoxia-inducible factors. Methods Enzymol 2007; 435: 221.
17. Haase VH,. Hypoxia-inducible factors in the kidney. Am J Physiol Renal Physiol 2006; 291: F271.
18. Han WQ, Zhu Q, Hu J, Li PL, Zhang F, Li N,. Hypoxia-inducible factor prolyl-hydroxylase-2 mediates transforming growth factor beta 1-induced epithelial-mesenchymal transition in renal tubular cells. Biochim Biophys Acta 2013; 1833: 1454.
19. Higgins DF, Kimura K, Iwano M, Haase VH,. Hypoxia-inducible factor signaling in the development of tissue fibrosis. Cell Cycle 2008; 7: 1128.
20. Tajima H, Higuchi O, Mizuno K, Nakamura T,. Tissue distribution of hepatocyte growth factor receptor and its exclusive down-regulation in a regenerating organ after injury. J Biochem 1992; 111: 401.
21. Liu Y,. Hepatocyte growth factor and the kidney. Curr Opin Nephrol Hypertens 2002; 11: 23.
22. Vargas GA, Hoeflich A, Jehle PM,. Hepatocyte growth factor in renal failure: promise and reality. Kidney Int 2000; 57: 1426.
23. Matsumoto K, Nakamura T,. Renotropic role and therapeutic potential of HGF in the kidney. Nephrol Dial Transplant 2002; 17 (Suppl 9): 59.
24. Franquesa M, Alperovich G, Herrero-Fresneda I, et al,. Direct electrotransfer of hHGF gene into kidney ameliorates ischemic acute renal failure. Gene Ther 2005; 12: 1551.
25. Mizuno S, Matsumoto K, Nakamura T,. HGF as a renotrophic and anti-fibrotic regulator in chronic renal disease. Front Biosci 2008; 13: 7072.
26. Liu Y,. Hepatocyte growth factor in kidney fibrosis: therapeutic potential and mechanisms of action. Am J Physiol Renal Physiol 2004; 287: F7.
27. Dai C, Liu Y,. Hepatocyte growth factor antagonizes the profibrotic action of TGF-beta1 in mesangial cells by stabilizing Smad transcriptional corepressor TGIF. J Am Soc Nephrol 2004; 15: 1402.
28. Yang J, Dai C, Liu Y,. Hepatocyte growth factor suppresses renal interstitial myofibroblast activation and intercepts Smad signal transduction. Am J Pathol 2003; 163: 621.
29. Azuma H, Takahara S, Matsumoto K, et al,. Hepatocyte growth factor prevents the development of chronic allograft nephropathy in rats. J Am Soc Nephrol 2001; 12: 1280.
30. Laping NJ, Olson BA, Ho T, Ziyadeh FN, Albrightson CR,. Hepatocyte growth factor: a regulator of extracellular matrix genes in mouse mesangial cells. Biochem Pharmacol 2000; 59: 847.
31. Pedersen EB, Hansen HE, Kornerup HJ, Madsen S, Sorensen AW,. Long-term graft survival after conversion from cyclosporin to azathioprine 1 year after renal transplantation. A prospective, randomized study from 1 to 6 years after transplantation. Nephrol Dial Transplant 1993; 8: 250.
32. Pedersen EB, Hansen HE, Olsen S, et al,. Comparison between the effects of cyclosporine and azathioprine on functional and morphologic renal parameters in a randomized study from 12 to 24 months after renal transplantation. Clin Transplant 1991; 5: 456.
33. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D,. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 1999; 130: 461.
34. Levey AS, Coresh J, Greene T, et al,. Using standardized serum creatinine values in the modification of diet in renal disease study equation for estimating glomerular filtration rate. Ann Intern Med 2006; 145: 247.
35. Johnson D,. The CARI guidelines. Evaluation of renal function. Nephrology (Carlton) 2005; 10: S133.
36. Racusen LC, Solez K, Colvin RB, et al,. The Banff 97 working classification of renal allograft pathology. Kidney Int 1999; 55: 713.
37. Nyengaard JR,. Stereologic methods and their application in kidney research. J Am Soc Nephrol 1999; 10: 1100.
38. Matsumoto K, Morishita R, Moriguchi A, et al,. Prevention of renal damage by angiotensin II blockade, accompanied by increased renal hepatocyte growth factor in experimental hypertensive rats. Hypertension 1999; 34: 279.
39. Yang J, Dai C, Liu Y,. Hepatocyte growth factor gene therapy and angiotensin II blockade synergistically attenuate renal interstitial fibrosis in mice. J Am Soc Nephrol 2002; 13: 2464.
40. Capuano A, Costanzi S, Peluso G, et al,. Hepatocyte growth factor and transforming growth factor beta1 ratio at baseline can predict early response to cyclophosphamide in systemic lupus erythematosus nephritis. Arthritis Rheum 2006; 54: 3633.
41. Taniguchi Y, Yorioka N, Yamashita K, et al,. Localization of hepatocyte growth factor and tubulointerstitial lesions in IgA nephropathy. Am J Nephrol 1997; 17: 413.
42. Wolf HK, Zarnegar R, Michalopoulos GK,. Localization of hepatocyte growth factor in human and rat tissues: an immunohistochemical study. Hepatology 1991; 14: 488.
43. Liu Y, Tolbert EM, Sun AM, Dworkin LD,. Primary structure of rat HGF receptor and induced expression in glomerular mesangial cells. Am J Physiol 1996; 271: F679.
44. Mizuno S, Matsumoto K, Kurosawa T, Mizuno H, Nakamura T,. Reciprocal balance of hepatocyte growth factor and transforming growth factor-beta 1 in renal fibrosis in mice. Kidney Int 2000; 57: 937.
45. Mizuno S, Matsumoto K, Nakamura T,. Hepatocyte growth factor suppresses interstitial fibrosis in a mouse model of obstructive nephropathy. Kidney Int 2001; 59: 1304.
46. Igawa T, Matsumoto K, Kanda S, Saito Y, Nakamura T,. Hepatocyte growth factor may function as a renotropic factor for regeneration in rats with acute renal injury. Am J Physiol 1993; 265: F61.
47. Matsumoto K, Nakamura T,. Hepatocyte growth factor: renotropic role and potential therapeutics for renal diseases. Kidney Int 2001; 59: 2023.
48. Yamaguchi K, Nalesnik MA, Michalopoulos GK,. Expression of HGF mRNA in human rejecting kidney as evidenced by in situ hybridization. Urol Res 1996; 24: 349.
49. Haase VH,. Pathophysiological consequences of HIF activation: HIF as a modulator of fibrosis. Ann N Y Acad Sci 2009; 1177: 57.
50. Rosenberger C, Pratschke J, Rudolph B, et al,. Immunohistochemical detection of hypoxia-inducible factor-1alpha in human renal allograft biopsies. J Am Soc Nephrol 2007; 18: 343.
51. Yu TM, Wen MC, Li CY, et al,. Expression of hypoxia-inducible factor-1alpha (HIF-1alpha) in infiltrating inflammatory cells is associated with chronic allograft dysfunction and predicts long-term graft survival. Nephrol Dial Transplant 2013; 28: 659.
52. Dosanjh A, Robison E, Mondala T, Head SR, Salomon DR, Kurian SM,. Genomic meta-analysis of growth factor and integrin pathways in chronic kidney transplant injury. BMC Genomics 2013; 14: 275.
53. Lohr JW, Lee TP, Farooqui M, Mookerjee BK,. Increased levels of serum hepatocyte growth factor in patients with end-stage renal disease. J Med 2000; 31: 131.
54. Liu Y, Rajur K, Tolbert E, Dworkin LD,. Endogenous hepatocyte growth factor ameliorates chronic renal injury by activating matrix degradation pathways. Kidney Int 2000; 58: 2028.
55. Gong R, Rifai A, Tolbert EM, Centracchio JN, Dworkin LD,. Hepatocyte growth factor modulates matrix metalloproteinases and plasminogen activator/plasmin proteolytic pathways in progressive renal interstitial fibrosis. J Am Soc Nephrol 2003; 14: 3047.
56. Esposito C, Parrilla B, De MA, et al,. Hepatocyte growth factor (HGF) modulates matrix turnover in human glomeruli. Kidney Int 2005; 67: 2143.
57. Mahmoud K, Opelz G, Pelzl S, et al,. Evaluation of hepatocyte growth factor as a sensitive marker for early detection of acute renal allograft rejection. Transplantation 2007; 83: 1035.